<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12804417
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     06
    </month>
    <day>
     13
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     07
    </month>
    <day>
     28
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1469-493X
     </issn>
     <journalissue citedmedium="Internet">
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2003
       </year>
      </pubdate>
     </journalissue>
     <title>
      Cochrane database of systematic reviews (Online)
     </title>
     <isoabbreviation>
      Cochrane Database Syst Rev
     </isoabbreviation>
    </journal>
    <articletitle>
     Initial management strategies for dyspepsia.
    </articletitle>
    <pagination>
     <medlinepgn>
      CD001961
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      This review considers management strategies (combinations of initial investigation and empirical treatments) for dyspeptic patients. Dyspepsia was defined to include both epigastric pain and heartburn.
     </abstracttext>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      To determine the effectiveness, acceptability, and cost effectiveness of the following initial management strategies for patients presenting with dyspepsia (a) initial pharmacological therapy (including endoscopy for treatment failures) (b) early endoscopy (c) testing for Helicobacter pylori and endoscope only those positive (d) H.pylori eradication therapy with or without prior testing.
     </abstracttext>
     <abstracttext label="SEARCH STRATEGY" nlmcategory="METHODS">
      Trials were located through electronic searches and extensive contact with trialists.
     </abstracttext>
     <abstracttext label="SELECTION CRITERIA" nlmcategory="METHODS">
      All randomised controlled trials of dyspeptic patients presenting in primary care.
     </abstracttext>
     <abstracttext label="DATA COLLECTION AND ANALYSIS" nlmcategory="METHODS">
      Data was collected on dyspeptic symptoms, quality of life and use of resources.
     </abstracttext>
     <abstracttext label="MAIN RESULTS" nlmcategory="RESULTS">
      Twenty papers reporting 23 comparisons were found. Trials comparing proton pump inhibitors (PPI) with antacids (two trials) and H2 receptor antagonists (three trials), early endoscopy with initial acid suppression (five trials), H.pylori 'test and scope' v usual management (three trials), H.pylori test and treat v. endoscopy (four trials), and test and treat v. acid suppression alone in H.pylori positive patients (two trials), were pooled. PPIs were significantly more effective than both H2RAs and antacids. Relative risks (RR) and 95% CI were, for PPI: antacid 0.72 (0.64-0.80), PPI: H2RA 0.63 (0.47-0.85). Results for other drug comparisons were either absent or inconclusive. Initial endoscopy was associated with a small reduction in the risk of recurrent dyspeptic symptoms compared with initial prescribing (RR 0.89 (0.77-1.02). H.pylori test and endoscopy increases costs in primary care, but does not improve symptoms. H.pylori test and eradicate may be as effective as endoscopy- based management and reduces costs, by decreasing the proportion of patients that are endoscoped. 'Test and treat' may be more effective than acid suppression alone, RR 0.59 (0.42-0.83).
     </abstracttext>
     <abstracttext label="REVIEWER'S CONCLUSIONS" nlmcategory="CONCLUSIONS">
      PPIs are effective in the treatment of dyspepsia in these trials which may not adequately exclude patients with gastro-oesophageal reflux disease. The relative efficacy of H2RA and PPI is uncertain. Early investigation by endoscopy or H.pylori testing may benefit some patients with dyspepsia. The review will be updated in 2004 with an individual patient data meta-analysis of the economic data, and a subgroup analysis by age and predominant dyspeptic symptom.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Primary Care and General Practice, Primary Care and Clinical Sciences Building, The University of Birmingham, Edgbaston, Birmingham, West Midlands, UK, B15 2TT. b.c.delaney@bham.ac.uk
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Delaney
      </lastname>
      <forename>
       B C
      </forename>
      <initials>
       BC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Moayyedi
      </lastname>
      <forename>
       P
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Forman
      </lastname>
      <forename>
       D
      </forename>
      <initials>
       D
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     Cochrane Database Syst Rev
    </medlineta>
    <nlmuniqueid>
     100909747
    </nlmuniqueid>
    <issnlinking>
     1361-6137
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Bacterial Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Gastrointestinal Agents
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="UpdateIn">
     <refsource>
      Cochrane Database Syst Rev. 2005;(4):CD001961
     </refsource>
     <pmid version="1">
      16235292
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="UpdateOf">
     <refsource>
      Cochrane Database Syst Rev. 2001;(3):CD001961
     </refsource>
     <pmid version="1">
      11687004
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Bacterial Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dyspepsia
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      microbiology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gastrointestinal Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gastroscopy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Helicobacter Infections
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Helicobacter pylori
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    75
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      6
     </month>
     <day>
      14
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      7
     </month>
     <day>
      29
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      6
     </month>
     <day>
      14
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12804417
    </articleid>
    <articleid idtype="doi">
     10.1002/14651858.CD001961
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

